Key Highlights:
- Capricor Therapeutics' drug deramiocel makes notable strides in treating Duchenne muscular dystrophy cardiomyopathy.
- Analysts predict an average price target of $43.71 for CAPR, signifying substantial growth potential.
- The stock's forecast shows a promising upside, with positive brokerage recommendations indicating an "Outperform" status.
Capricor Therapeutics' Progress in Duchenne Muscular Dystrophy Treatment
Capricor Therapeutics (NASDAQ: CAPR) continues to advance its innovative drug, deramiocel, designed to treat Duchenne muscular dystrophy (DMD) cardiomyopathy. CEO Linda Marban has confirmed significant progress on the Biologics License Application, highlighting the drug's robust safety profile. In a strategic move to strengthen their leadership, Capricor has appointed Dr. Michael Binks as the new Chief Medical Officer, bringing valuable expertise to the team.
Wall Street Analysts Forecast for CAPR
According to projections from seven analysts, the average one-year price target for Capricor Therapeutics Inc (CAPR, Financial) is $43.71, with estimates ranging from a high of $77.00 to a low of $25.00. This average target suggests a remarkable upside of 498.83% from the current price of $7.30. For more comprehensive insights, visit the Capricor Therapeutics Inc (CAPR) Forecast page.
Brokerage Recommendations
The consensus among seven brokerage firms places Capricor Therapeutics Inc's (CAPR, Financial) average recommendation at 1.7, classifying it as "Outperform." The recommendation scale spans from 1 (Strong Buy) to 5 (Sell), reflecting a strong investor sentiment toward the stock's potential.
Capricor's GF Value and Future Potential
GuruFocus estimates indicate that the GF Value for Capricor Therapeutics Inc (CAPR, Financial) in the coming year is $15.92, pointing to an upside of 118.08% from its current trading price of $7.30. The GF Value represents GuruFocus' assessment of the fair value at which the stock should be traded. This calculation considers the stock's historical trading multiples, past business growth, and future performance projections. Detailed data is available on the Capricor Therapeutics Inc (CAPR) Summary page.
